rm 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	10/750,326		
Filing Date	December 31, 2003		
First Named Inventor	Jeffrey O. Saunders		
Group Art Unit	1714- 1624		
Examiner Name	Not Yet Assigned		
Attorney Docket Number	VPI/02-142 US		

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreig Office	n Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
TNIV	B 1	wo	95/15963	BASF Aktiengesellschaft	15 June 1995	
~	B2	wo	98/18781	Versicor, Inc.	7 May 1998	
V	В3	wo	98/56770	BASF Aktiengesellschaft	17 December 1998	
INTU	∕B4	EP	0 456 835	Kyorin Pharmaceutical Co., Ltd.	21 November 1991	

	OTHER NON-PATENT LITERATURE DOCUMENTS					
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
TMT	C1	Malamas, et al., "Quinazolineacetic Acids and Related Analogues as Aldose Reductase Inhibitors", J. Med. Chem., Vol. 34, No. 4, pp. 1492-1503 (1991).				
TNT	C2	Gordeev, et al., "A General and Efficient Solid Phase Synthesis of Quinazoline-2,4-diones.", Tetrahedron Letters, Vo. 38, No. 10, pp. 1729 -1732 (1997).				

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. ______, filed ______, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Mom	Date Considered	7110106
-----------------------	-----	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.